SCHEMBL968472

SCHEMBL968472

C=CC(=O)OC1=NCC(=O)O1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TYMS P04818 1/20 0.33
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL965609 0.69 THRB (0.31) THRB
SCHEMBL27588638 0.65
SCHEMBL9634486 0.61 THRB (0.38) TYMSTHRB
SCHEMBL28495445 0.59 THRB (0.35) THRB
SCHEMBL27620733 0.59 LMNA (0.33) THRB
SCHEMBL2579041 0.59 THRB (0.41) THRB
SCHEMBL10789483 0.59
SCHEMBL13899925 0.58 TYMS (0.52) TYMSTHRB
SCHEMBL11850804 0.58 THRB (0.48) TYMSTHRB
SCHEMBL2587522 0.58 THRB (0.64) TYMSTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279731-B2 Ligand functional substrates 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-03-22 US disclosed
US-11111320-B2 Addition-fragmentation oligomers 3M INNOVATIVE PROPERTIES COMPANY (US) 2021-09-07 US disclosed
EP-3326711-B1 GRAFT COPOLYMER FUNCTIONALIZED ARTICLE 3M INNOVATIVE PROPERTIES CO (US) 2021-07-07 EP disclosed
EP-2675783-B1 ADDITION-FRAGMENTATION AGENTS 3M INNOVATIVE PROPERTIES CO (US) 2020-04-22 EP disclosed
EP-3259323-B1 ADDITION-FRAGMENTATION OLIGOMERS 3M INNOVATIVE PROPERTIES CO (US) 2020-02-26 EP disclosed
US-20200031961-A1 ADDITION-FRAGMENTATION OLIGOMERS 3M INNOVATIVE PROPERTIES CO (US) 2020-01-30 US disclosed
US-10479848-B2 Addition-fragmentation oligomers 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-11-19 US disclosed
US-10471398-B2 Graft copolymer functionalized article 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-11-12 US disclosed
US-10370322-B2 Addition-fragmentation agents 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-08-06 US disclosed
EP-3502092-A1 ADDITION-FRAGMENTATION AGENTS 3M Innovative Properties Company (US) 2019-06-26 EP disclosed
US-6677402-B2 PHOTOPOLYMERIZATION 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed
US-20030216519-A1 Reactive oligomers 3M INNOVATIVE PROPERTIES COMPANY 2003-11-20 US disclosed
US-20030212210-A1 Reactive oligomers 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-6635690-B2 Step growth crosslinkable materials 3M INNOVATIVE PROPERTIES COMPANY 2003-10-21 US disclosed
US-20030114553-A1 Hardenable self-supporting structures and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2003-06-19 US disclosed
US-20030096908-A1 Reactive oligomers 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20020132927-A1 Pressure sensitive adhesives possessing high load bearing capability 3M INNOVATIVE PROPERTIES COMPANY 2002-09-19 US disclosed
US-6448337-B1 CURABLE SYRUP COMPRISING DUAL POLYMERS CONTAINING PENDANT INTERREACTIVE GROUPS, FREE RADICAL POLYMERIZABLE SOLVENT MONOMER AND PHOTOINITIATOR; BALANCED ADHESIVE AND COHESIVE CHARACTERISTICS 3M INNOVATIVE PROPERTIES COMPANY 2002-09-10 US disclosed
EP-0808348-B1 CROSS-LINKABLE PRESSURE SENSITIVE ADHESIVE AND PROCESS FOR THE PRODUCTION OF AN ARTICLE COATED WITH A CROSSLINKED PRESSURE SENSITIVE ADHESIVE MINNESOTA MINING & MFG (US) 1999-05-06 EP disclosed
US-5741543-A CONTAINING UNSATURATED MONOMERS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479848-B2 Addition-fragmentation oligomers ECPAS, ITGA8, NBAS TYMS 2854/4885THRB 4239/4885
US-10370322-B2 Addition-fragmentation agents NR4A1, PARP14, MTX1 TYMS 3022/4885THRB 2735/4885
US-20200031961-A1 ADDITION-FRAGMENTATION OLIGOMERS ECPAS, ITGA8, NBAS TYMS 2854/4885THRB 4239/4885
US-11279731-B2 Ligand functional substrates PCNA, POLM, POLL TYMS 1374/4885THRB 3995/4885
US-11111320-B2 Addition-fragmentation oligomers ECPAS, ITGA8, NBAS TYMS 2854/4885THRB 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.